KCL-286 Boosts DNA Repair in Alzheimer’s Mice as Phase 1 Safety Clears Human Hurdle
Updated
Updated · Drug Target Review · Jul 9
KCL-286 Boosts DNA Repair in Alzheimer’s Mice as Phase 1 Safety Clears Human Hurdle
3 articles · Updated · Drug Target Review · Jul 9
Summary
New FEBS Open Bio data showed KCL-286 improved neuronal DNA repair and cut inflammation in a mouse model of Alzheimer’s disease.
KCL-286 activates the retinoic acid receptor-β, triggering a pathway that helps a protein complex bind DNA and switch on repair genes.
The treatment also reduced abnormal brain immune activity, a process linked to Alzheimer’s progression alongside neuronal damage.
Phase 1 trials have already found a favorable human safety profile, and the King’s College London team said the next step is patient testing if funding is secured.
Researchers said the DNA-repair approach could extend beyond Alzheimer’s to broader nerve repair and neurodegenerative disease.
By repairing brain DNA, could a new drug reverse Alzheimer's damage instead of just slowing its progression?
Could targeting DNA damage be the master key to treating all neurodegenerative diseases, not just Alzheimer's?
Could activating a powerful DNA repair gene in the brain also carry unforeseen risks for healthy neurons?
KCL-286 Advances Alzheimer’s Drug Pipeline with Dual Mechanism and Accelerated Clinical Development
Overview
KCL-286 is a promising new drug for Alzheimer's disease, standing out as a first-in-class, orally available molecule that selectively activates retinoic acid receptor-β. Recent preclinical studies show that KCL-286 can address multiple underlying causes of Alzheimer's at once by targeting several disease-relevant pathways, including those that start early in the disease. Notably, it tackles key pathological mechanisms such as neuronal DNA damage and inflammation, and researchers have observed that it can improve these issues in disease models. This multi-targeted approach suggests KCL-286 could become an effective disease-modifying therapy for Alzheimer's.